Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Peripheral Artery Disease (PAD)
Interventions
DRUG

GM-CSF

Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.

DRUG

Placebo

Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.

Trial Locations (1)

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Emory University

OTHER